Skip to content
Next results · Q4 2026Projected

Mar 17, before the open

Wed, Mar 17, 2027in 120 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 10 – Apr 2

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$9.12M
Revenue, change from a year earlier: Q3 2026 +22.8%, Q2 2026 +27.1%, Q1 2026 +233.7%, Q4 2025 −49.9%
Net income
-$5.50M
Net income, change from a year earlier: Q3 2026 +68.2%, Q2 2026 +2,203.0%, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 +66.7%, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 ±0.0%

Results day

Typical moveA typical move of 10.5% either way

Up after 5 of 12, down after 7.

The stock’s move from the last close before each release to the first close after it, over the last 12 releases. Largest: −40.1% after Q1 2025.

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

When it reports

Usual day
Varies
Session
before the open
After quarter end
41 to 76 days
10-Q filed
41 to 45 days
over its last 8
10-K filed
72 to 89 days
over its last 8

Based on 8 prior 10-K filings.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR